Daniel Froehlich becomes Head of Finance at Endogena Therapeutics
Zuerich, Switzerland – January 2023 After a long career in different areas of finance and controlling for stock market-listed Swiss multinational groups, SMEs, in different industries, such as medical technology, Daniel decided to join the start-up, biotech pharmaceutical industry. His extensive experience as a CFO and COO will be crucial for our growing company. “We […]
Endogena Therapeutics Receives US FDA Fast Track Designation for EA-2353 for the Treatment of Retinitis Pigmentosa
San Francisco, USA; Toronto, Canada; Zürich, Switzerland, February 6, 2023 Endogena Therapeutics Inc., a clinical-stage biotech company focused on thedevelopment of endogenous regenerative medicines, announced today that the USFood and Drug Administration (FDA) has designated the investigation of EA-2353 forthe treatment of retinitis pigmentosa (RP) as a Fast Track developmentprogram. Fast Track is a process […]
Between science fiction… and biblical miracle
Translated from the SonntagsBlick Magazin 27 November 2022 Inherited blindness is almost impossible to treat. Now there is hope – even if the project of Matthias Steger’s Swiss biotech company still sounds futuristic. KATJA RICHARD AUTHOR AND THOMAS MEIER IMAGES Read more DE: https://www.blick.ch/life/lichtblick-fuer-erblindete-zwischen-science-fiction-und-biblischem-wunder-id18087615.html EN: https://endogena.com/wp-content/uploads/2022/12/29_11_22-Sobli_ENG-translated.pdf
Sven Weiler joins Endogena as VP Medicinal Chemistry
We are pleased to announce that Sven Weiler has joined our team in Schlieren, Switzerland as Vice President Medicinal Chemistry on August 1st, 2022. “I very much look forward to becoming an integral part of Endogena Therapeutics and to extend my expertise among this passionate group of colleagues. It’s exciting to be joining a company […]
Endogena receives Retina Innovation Award at event showcasing new therapies for eye conditions
July 13th, New York, NY Poignantly crafted from the clearest crystal, the Retina Innovation Award that now claims pride of place in Endogena Therapeutics’ trophy cabinet represents how far the company has come in developing a potential new treatment for people losing their sight because of retinitis pigmenosa (RP). More than 350 international delegates including clinicians, […]
Endogena Therapeutics transitions into clinical stage with its novel regenerative treatment for blindness caused by retinitis pigmentosa
Zürich, Switzerland and Toronto, Canada; 12th July 2022 Endogena Therapeutics Inc. announced today that the first patient has been treated in a phase 1/2a clinical study of its lead product, EA-2353, a photoreceptor regeneration treatment for retinitis pigmentosa (RP). RP is a group of inherited diseases causing slow and progressive retinal degeneration and loss of […]
Michael Lai joins Endogena as Medical Director
As Endogena Therapeutics is moving into the next phase from a pre-clinical to a clinical stage company, we are pleased to announce that Michael Lai has joined our team as Medical Director Clinical Development on April 1st, 2022. “We are excited to kick-off this critical stage in our company’s development with such a high-profile candidate […]
EA-2353 has the potential to reverse the loss of vision in patients with Retinitis Pigmentosa
Watch now …
Endogena Completes Series A with Total Funding of $29 million to Progress Treatments for Degenerative Diseases of the Eye
We are thrilled today to announce that its largest shareholder and lead operating partner Rejuveron Life Sciences AG, has committed a further $20 million funding to progress treatments targeting degenerative diseases of the eye. With an additional $1 million from existing investors, Endogena has now completed its $29 million Series A financing round. Matthias Steger, […]
FDA grants orphan drug designation for Endogena’s lead program targeting retinitis pigmentosa
First small-molecule cell regeneration treatment to be developed for the leading cause of inherited blindness Endogena Therapeutics Inc., which discovers and develops endogenous regenerative medicines, announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for its EA-2353 ophthalmic suspension targeting retinitis pigmentosa, a rare condition that causes slow and […]